Division of Cerebrovascular Diseases, Department of Neurology, University of Iowa Carver College of Medicine, 200 Hawkins Drive, 2148 RCP, Iowa City, IA, 52242, USA.
CNS Drugs. 2014 Nov;28(11):1035-45. doi: 10.1007/s40263-014-0204-0.
Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
静脉注射重组组织型纤溶酶原激活剂（rt-PA 或阿替普酶）是唯一在症状发作后最初数小时内批准用于治疗急性缺血性脑卒中的医学干预手段。本文回顾了 rt-PA 在急性缺血性脑卒中治疗中的初步研究，这些研究促成了美国 FDA 批准在症状发作后 3 小时内使用 rt-PA。本文还讨论了 rt-PA 在症状发作后 3 小时以上使用的研究和未来的再灌注治疗。本文还描述了急性缺血性脑卒中的临床表现和治疗以及脑卒中护理系统。
